Pacific Biosciences of California | ARS:年度报告
Pacific Biosciences of California | DEFA14A:其他
Pacific Biosciences of California | DEF 14A:股东委托书决议
Pacific Biosciences of California | 8-K:PacBio 公布 2024 年第一季度初步收入和更新 2024 年收入指引宣布计划将 2024 年第一季度年化运营费用运行率降低 5,000 万至 7,500 万美元的 2024 年第一季度财报电话会议定于 2024 年 5 月 9 日举行
Pacific Biosciences of California | PRE 14A:并购重组委托声明
Pacific Biosciences of California | POSASR:注册声明修正稿
Pacific Biosciences of California | POSASR:注册声明修正稿
Pacific Biosciences of California | POSASR:注册声明修正稿
Pacific Biosciences of California | 4:持股变动声明-董事 ORDONEZ KATHY
Pacific Biosciences of California | 4:持股变动声明-董事 Meline David W
Pacific Biosciences of California | 4:持股变动声明-高管 Farmer Michele
Pacific Biosciences of California | 4:持股变动声明-高管 Van Oene Mark
Pacific Biosciences of California | 4:持股变动声明-高管 Kim Susan G.
Pacific Biosciences of California | 4:持股变动声明-高管 HENRY CHRISTIAN O
Pacific Biosciences of California | 4:持股变动声明-董事 MOHR MARSHALL
Pacific Biosciences of California | 144:拟议出售证券
Pacific Biosciences of California | 144:拟议出售证券
Pacific Biosciences of California | 144:拟议出售证券
Pacific Biosciences of California | S-8:员工福利计划证券登记
Pacific Biosciences of California | 10-K:年度报表
暂无数据